NMN and NR in 2026: what the research actually says, where it got complicated, and what it means for your stack
TL;DR: NAD precursors (NMN and NR) do raise NAD levels in blood and some tissues. Whether that translates to meaningful human outcomes is more complicated than the supplement industry wants you to believe and more interesting than the skeptics allow. tissue-specific evidence matters more than whole-blood NAD numbers, the 70-plus population has the most consistent signal, and a major 2026 study just complicated the narrative in ways worth understanding.
Now, the long post.
When I wrote the original NMN buying guide the science was already more contested than the marketing suggested. It's gotten more interesting since. This post is an attempt to give you an honest state of play, specifically around the question a user I will mention in the comments raised; where in the body do we actually see NAD levels rising, and what are the implications?
The background you need first if you are brand new to NAD+
NAD (nicotinamide adenine dinucleotide) is a coenzyme involved in hundreds of metabolic reactions, central to energy production, DNA repair via PARP enzymes, and sirtuins (the longevity proteins that Sinclair's lab helped make famous). The popular premise of NMN and NR supplementation is that NAD declines with age, that low NAD drives aging-associated decline in multiple systems, and that supplementing precursors can restore levels and slow or reverse that decline.
That premise is where the science started getting complicated.
The 2026 complication
Tretowicz et al., published in Nature Metabolism in 2026 (I will thank the person who shared this again and again in the comments), measured whole-blood NAD levels across a large human cohort spanning multiple age groups and lifestyle categories. The headline finding is whole-blood NAD does not meaningfully decline with age, and lifestyle interventions including exercise did not produce the NAD increases the preclinical literature predicted.
This landed as a significant counterweight to the decline narrative because most of the earlier human data showing age-related NAD decline used peripheral blood mononuclear cells (PBMCs) or whole blood as the measurement substrate. If the decline isn't there in whole blood, a central pillar of the supplementation rationale weakens.
But here is where it gets more nuanced, and why I don't think this paper ends the conversation.
WHOLE BLOOD IS NOT THE TISSUE THAT MATTERS
NAD biology is tissue-specific in ways that whole-blood measurements obscure. The NAD you can measure in blood reflects red blood cells and circulating immune cells. Red blood cells are metabolically unusual and their NAD content is not representative of what's happening in muscle, brain, liver, or adipose tissue, which are the compartments where NAD-dependent processes most relevant to aging actually occur.
The Yoshino lab's human work, and the Yi et al. RCT using Uthever-sourced NMN, measured functional outcomes (muscle insulin sensitivity, physical performance markers) rather than relying solely on blood NAD as a proxy. The argument those trials are making is not "blood NAD went up therefore aging slowed." It's "we gave NMN, we measured functional endpoints in muscle, and we saw improvements." That's a different and arguably more relevant claim.
The Tretowicz finding is important because it should kill the simplistic "NAD declines with age, supplement to restore" marketing narrative. It does not necessarily invalidate the intervention data showing functional benefits in specific tissues and populations, because those benefits may operate through mechanisms that don't require whole-blood NAD to move.
So, where the precursor actually goes?
NMN and NR don't behave identically after ingestion and the route matters for where NAD ends up.
NR is absorbed intact in the small intestine, enters cells, and is converted to NMN then to NAD. Relatively straightforward oral bioavailability. Raises blood NAD reliably in human studies. The question is whether blood NAD reflects tissue NAD in the compartments you care about.
NMN's oral bioavailability story got more complicated with a 2023 paper showing that a significant portion of orally ingested NMN is converted to nicotinamide (niacinamide) in the gut before absorption, then reconverted to NAD via the salvage pathway in tissues. This is actually fine mechanistically, the salvage pathway is efficient, but it means the NMN you're swallowing may not be arriving at tissues as NMN. It may be functionally similar to taking nicotinamide at an equivalent dose. The clinical implication is debated. The practical implication is that the specific form of precursor may matter less than the industry suggests, and that the NMN premium over NR or even nicotinamide may not be justified for all users.
Sublingual NMN was proposed as a route that bypasses gut conversion and delivers intact NMN directly to circulation. Some human pharmacokinetic data supports faster and higher plasma NMN peaks with sublingual vs oral. Whether this translates to better tissue NAD outcomes in the compartments that matter is not yet established in long-term human trials.
The human evidence
Being totally honest about where the human evidence actually supports meaningful benefit:
- Skeletal muscle in older adults. This is the most consistent finding across trials. The Yoshino work in postmenopausal women, the Yi et al. RCT in older adults, and other trials show improvements in muscle insulin sensitivity and in some cases physical performance metrics. The effect sizes are modest but reproducible. For a 70-plus person with sarcopenia risk, this is the most defensible use case.
- Metabolic function. Multiple trials show improvements in insulin sensitivity markers with both NMN and NR, particularly in metabolically compromised or older populations. Less clear in already metabolically healthy younger adults.
- Potentially the brain. NAD is critical for neuronal energy metabolism and DNA repair. There is mechanistic rationale and some animal data for cognitive protection. Human trials specifically on cognitive endpoints in aging are underway but the data isn't mature. This is a watch-this-space finding rather than an established benefit.
Where the evidence is weak; or completely absent
- Younger, healthy adults. Most of the positive functional outcome data comes from older or metabolically compromised populations. The NAD precursor case for a healthy 35-year-old is mechanistically interesting but not well supported by human outcome data. You're probably optimizing a system that isn't the limiting factor yet.
- Cardiovascular endpoints. There is preclinical data and mechanistic rationale. There are no clean human RCTs showing hard cardiovascular outcome benefits from NAD precursor supplementation. The CANTOS and similar trials targeting inflammation showed what targeting a single pathway in a complex system looks like. NAD is more upstream but the human outcome data isn't there yet.
- Longevity itself. No human lifespan data exists and won't for obvious reasons. The animal data is impressive and has driven enormous investment. The translation to humans is genuinely unknown.
The Sinclair backdrop and why it matters for how you read the literature
David Sinclair's lab has been central to the sirtuin and NAD narrative and has financial relationships with supplement and longevity companies. ChromaDex (which makes Tru Niagen, the main NR commercial product) and various NMN companies have funded research directly or indirectly. This doesn't make the science wrong, but it means you should read the mechanistic enthusiasm in some papers through that lens. The trials with the clearest positive findings have generally been from independent labs (Yoshino at Washington University, Sekhar at Baylor) rather than from industry-funded work.
The practical implications for your stack
- If you're 50-plus with metabolic or muscle function goals, NAD precursor supplementation has more defensible human evidence than almost any other longevity compound in that category. The Tretowicz whole-blood finding doesn't undo the muscle insulin sensitivity and functional outcome data. Dose in the 500mg to 1000mg NMN range or equivalent NR.
- If you're under 40 and metabolically healthy, the case is weaker. The limiting factor in your NAD biology may not be precursor availability. Diet, sleep, and resistance training do more for NAD-relevant pathways than supplementation at your age.
- If you're taking NMN or NR, add TMG (500mg to 1g daily). The methyl donor consumption is real and worth taking seriously regardless of where you land on the efficacy debate.
- Source quality still matters regardless of efficacy debate. Uthever and EffePharm certified supply chain, quantitative COA showing beta isomer purity, not just presence certification. This hasn't changed.
- The stop-test framework applies here as it does everywhere. Twelve weeks minimum on a consistent dose before evaluating. Drop for four to six weeks and observe whether anything degrades. Subjective feel is not nothing but it's not sufficient on its own. If you can get skeletal muscle insulin sensitivity proxies (fasting insulin, HOMA-IR) before and after, that's the closest functional endpoint to what the positive trials are measuring that you can actually access through standard labs.
The honest bottom line is that the NAD precursor story is more complicated than it was three years ago, more interesting than the dismissers allow, and considerably less certain than the marketers claim. That's where the science actually is.
Not medical advice though. Discuss any additions with your doctor, particularly if you're on medications affecting glucose metabolism or methylation.
Let's discuss.